ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMLN Stock Price » AMLN Stock News

Amylin Pharmaceuticals Share News

 Amylin Pharmaceuticals (mm) Stock Price
AMLN Stock Price
 Amylin Pharmaceuticals (mm) Stock Chart
AMLN Stock Chart
 Amylin Pharmaceuticals (mm) Stock News
AMLN Stock News
 Amylin Pharmaceuticals (mm) Company Information
AMLN Company Information
 Amylin Pharmaceuticals (mm) Stock Trades
AMLN Stock Trades

Icahn Firm's Denner Might Leave To Start Hedge Fund -Bloomberg

DOW JONES NEWSWIRES Alexander Denner, senior managing director of Icahn Partners LP (IEP) and a leading player in health care investments by firm founder Carl Icahn, is considering leaving to start his own hedge fund, Bloomberg News reported Thursday, citing two people with knowledge of the plan. Denner, 42 years old, would open his fund firm by the end of this year, and Icahn might invest in it, one of the sources told Bloomberg. Icahn wasn't available to comment, the news service cited an assistant to the famed activist investor as saying. Since joining Icahn's New York firm in 2006, Denner has been instrumental in management shuffles, efforts to boost sales or restructurings of at least six pharmaceutical companies. He is chairman of Enzon Pharmaceuticals Inc. (ENZN) and serves on the boards of Biogen Idec Inc. (BIIB) and Amylin Pharmaceuticals Inc. (AMLN). An Icahn team led by Denner failed in August to win representation on Forest Laboratories Inc.'s (FRX) board after the drugmaker proposed three new directors of its own. Full story at -Dow Jones Newswires; 212-416-2900

Stock News for Amylin Pharmaceuticals (AMLN)
No Recent News Available

Amylin Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations